
Opinion|Videos|February 28, 2025
Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences
Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) while also considering how these factors align or differ from patient preferences regarding treatment duration, adverse effect profiles, and lifestyle impact.
Advertisement
Episodes in this series

- What clinical and patient-specific factors influence your treatment selection between BTK inhibitors for treatment-naive patients with CLL and MCL?
- How do your factors align with or differ from your patients’ preferences and values?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
2
It’s Time to Reimagine Reimbursement for CAR T-Cell Therapy
3
What ACA Subsidy Expiration Means for Coverage Costs, Employer Strategy, and ICHRAs: Q&A With Ben Light
4
Fee-for-Service Models Linked to Higher Odds of Low-Value Surgical Procedures
5
















































